Navigation Links
NIAID media availability: Still searching for predictors of asthma attacks
Date:8/10/2009

A new study of persistent asthma in inner-city adolescents and young adults finds that an extensive set of clinical tests cannot successfully predict the future risk of asthma attacks in participants who both receive care based on current guidelines and adhere to treatment recommendations. This finding differs from previous reports suggesting that certain clinical findings and laboratory tests could help predict future asthma attacks. These earlier conclusions, however, were based on observations of patients with poorly controlled asthma who had not received care based on current guidelines.

The study was conducted by the Inner City Asthma Consortium (ICAC), a nationwide network of clinical researchers supported by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. ICAC member Rebecca Gruchalla, M.D., Ph.D., from the University of Texas Southwestern Medical Center in Dallas, led the study. Additional support for the research was provided by the NIH National Center for Research Resources.

The 46-week study included 546 adolescents and young adults (ages 12 to 20 years old) in 10 cities across the United States. At the start of the study, ICAC investigators gathered baseline data by conducting standard tests to assess asthma symptoms. An additional battery of tests evaluated lung inflammation, lung function and allergic status. The participants were then seen every 6 to 8 weeks at their respective ICAC centers, where they were they were treated for asthma based on NIH guidelines developed by the National Asthma Education and Prevention Program. During the study, the participants carefully adhered to their treatment regimens.

After the study was completed, the investigators analyzed the baseline measurements to determine if any of these assessments, alone or in combination, could predict future asthma symptoms or asthma attacks. The investigators observed no significant clinical cor
'/>"/>

Contact: Julie Wu
wujuli@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. NIAID funds $51M contract to create comprehensive model of immune responses
2. NIAID strengthens and expands Vaccine and Treatment Evaluation Units
3. NIAID scientists identify new cellular receptor for HIV
4. NIAID to convene HIV Vaccine Summit
5. NIAID describes research priorities to fight drug-resistant tuberculosis
6. NIAID to advance B-cell approach to HIV vaccines
7. NIAID creates HIV vaccine discovery branch
8. NIAID awards contracts to search for protein markers of disease
9. NIAID media availability: Seizures following parasitic infection associated with brain swelling
10. NIAID honors AIDS activist Martin Delaney
11. NIAID and Chinese officials sign agreement to foster TB research in Chinas Henan province
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 23, 2013 Amirsys, Inc. will ... learning environment for all resident levels this July. ... transforms the learning experience from case-based learning to ... , “Until RADPrimer 3.0, RADPrimer heavily emphasized a ... Dr. B.J. Manaster, Professor of Radiology at the ...
(Date:5/23/2013)... it when a woman harried by hot flashes says ... study published online in Menopause , the journal ... with objective tests that what these women say about ... studies showed that hot flashes were related to memory ... though there was a relationship between hot flashes and ...
(Date:5/23/2013)... dragged to its destruction inside a cell, a ... that thwart the development of tumor-suppressing microRNAs (miRNAs) ... online publication at Nature . , Under ... the epidermal growth factor receptor (EGFR) gums up ... by scientists at The University of Texas MD ...
(Date:5/23/2013)... New York, New York (PRWEB) May 23, 2013 ... products manufactured by C.R. Bard, Inc., continue to move ... District Court, Southern District of West Virginia, Bernstein Liebhard ... 17th, the Court denied a request by C.R. Bard ... claimed would reveal trade secrets and other confidential, proprietary ...
(Date:5/23/2013)... New York, NY (PRWEB) May 23, 2013 ... http://bit.ly/Z4m6UI , Canadian tech start-ups are increasingly seeing ... deals with larger US-based companies, according to ... business development engine. , The company has compiled ... entitled Borderless Investments. The findings of the research have ...
Breaking Medicine News(10 mins):Health News:RADPrimer 3.0 Introduces Comprehensive Radiology Training Curriculum 2Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 2Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 3Health News:Transvaginal Mesh Lawsuits Move Forward, as Bernstein Liebhard LLP Notes New Order in Federal C.R. Bard Mesh Implant Lawsuits 2Health News:Transvaginal Mesh Lawsuits Move Forward, as Bernstein Liebhard LLP Notes New Order in Federal C.R. Bard Mesh Implant Lawsuits 3Health News:Merrill DataSite Releases New Comments: Trends amidst Canadian and US Tech M&A 2Health News:Merrill DataSite Releases New Comments: Trends amidst Canadian and US Tech M&A 3Health News:Merrill DataSite Releases New Comments: Trends amidst Canadian and US Tech M&A 4
... The National Commander of the Disabled American Veterans begins ... support for budget reform legislation to ensure sufficient, timely ... is urging them to reject a contentious proposal that ... conditions from the government,s side of the ledger to ...
... cranberriesand not the acidity of cranberry juice, as previously ... line the urinary tract, as documented in a report ... peer-reviewed journal published by Mary Ann Liebert, Inc. ( ... www.liebertpub.com/jmf , Urinary tract infections (UTIs) burden ...
... March 9 Quest Diagnostics Incorporated (NYSE: ... information and services, announced that it is scheduled to ... on Tuesday, March 10, 2009. The Quest Diagnostics ... Time.During the conference, the company will reaffirm its 2009 ...
... Sport Beans and Nike Motivate College Students to Complete ... SpringNEW YORK, March 9 American Collegiate Intramural Sports ... corporate sponsors are joining together to launch ACIS Fitness ... college marketing platform is aimed at motivating the 2.7 ...
... Japanese scientists will arrive at the University of Houston ... that promises to deliver more comprehensive and accurate insights ... of current technologies. , In April, Mikio Kubota of ... join the research team at UH,s Biomedical Imaging Lab. ...
... President Obama signed an executive order ... stem cell research, overturning limits on federal funding for ... President & CEO of Americans United for Life responded, ... past. Millions of dollars have been spent on ...
Cached Medicine News:Health News:Disabled Veterans Leader Presses Issues with Key Lawmakers 2Health News:New research reveals how cranberry products prevent urinary tract infections 2Health News:Quest Diagnostics to Speak at Barclays Capital Global Healthcare Conference 2Health News:ACIS Fitness Challenges Launch Across 200 Colleges Nationwide 2Health News:UH research team developing new noninvasive brain-mapping technology 2Health News:UH research team developing new noninvasive brain-mapping technology 3Health News:UH research team developing new noninvasive brain-mapping technology 4Health News:Americans United for Life: Obama Administration Stem Cell Policy an Anti-Life Waste of Tax Dollars 2
(Date:5/23/2013)... YORK , May 23, 2013  Intercept Pharmaceuticals, ... stage biopharmaceutical company focused on the development and commercialization ... diseases, such as primary biliary cirrhosis, today announced that ... Chief Executive Officer, will present at the Deutsche Bank ... Boston on Wednesday, May 29, 2013 at ...
(Date:5/23/2013)...  MedVantx, Inc., the company that has pioneered a ... the Company has completed a major expansion of its ... and the upgrade of its systems to offer a ... specialty home delivery pharmacy in Sioux Falls, ... physicians, health systems and payors novel distribution services, as ...
(Date:5/23/2013)... PARIS , May 23, 2013 ... (NYSE MKT: NSPR), the leader in embolic protection ... MASTER (MGuard for Acute ST Elevation Reperfusion) trial ... outperformed bare metal and drug eluting stents in ... (STEMI) patients.  Results from the trial were presented ...
Breaking Medicine Technology:MedVantx Achieves Significant Milestone of Managing $1.5B in Prescription Medications and Completes Facilities Expansion While Upgrading To Offer Current Good Manufacturer Practices (cGMP)-level Quality Systems in their Home Delivery Pharmacy 2MedVantx Achieves Significant Milestone of Managing $1.5B in Prescription Medications and Completes Facilities Expansion While Upgrading To Offer Current Good Manufacturer Practices (cGMP)-level Quality Systems in their Home Delivery Pharmacy 3InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 2InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 3InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 4InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 5
... FOREST, Ill., Sept. 6, 2011 Hospira, Inc. ... in generic injectable pharmaceuticals, today announced positive results from ... erythropoietin (EPO) in patients with renal (kidney) dysfunction who ... equal pharmacokinetics, or blood level and distribution in the ...
... 2011 Johnson & Johnson (NYSE: JNJ ) ... Tuesday, September 13 th , at the Grand Hyatt New ... New York, NY.  Dominic Caruso, Vice President, Finance and Chief ... the company in a session scheduled at 10:20 a.m. (Eastern). ...
Cached Medicine Technology:Hospira Announces Positive Results From Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients 2Hospira Announces Positive Results From Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients 3
... design of Sleepscan VISION ensures flexibility in ... opportunities. Sleepscan VISION utilizes the powerful Netlink ... through a standard Ethernet connection. Only computer ... allowing the Sleepscan VISION to take advantage ...
... Digital EEG ,The company that introduced ... the latest addition to the Ceegraph ... innovative system incorporates the latest developments ... management to offer you unprecedented portability, ...
... MOBEE headboxes are ... XLTEK's line of portable ... with a robust new ... latest software, XLTEK's standard ...
... SL 130 Slit Lamp is an all-in-one instrument ... structured design also allows the SL 130 to ... achieved by the possibility of operating the slit ... left or right hand. The instrument configuration allows ...
Medicine Products: